menu
    • menu

    Company profile for ImmunityBio

    NEW Drugs in Dev: 45
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    Evonik Health Care is the innovation hub for leading life science companies

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    REF. STANDARDS & IMPURITIES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Inducing Immunogenic Cell Death By Orchestrating the Innate (NK) and Adaptive (T Cell) Immune System. ImmunityBio, Inc. is a privately held immunotherapy company with one of the broadest portfolios of biological molecules spanning albumin-linked chemotherapeutic, peptides, fusion proteins, cytokine, monoclonal antibodies, adenovirus and yeast vaccine therapies.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    ImmunityBioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Culver City, CA 90232
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://immunitybio.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/immunitybio/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    International Sweetener Colloquium

    Not Confirmed

    envelop Contact Supplier

    International Sweetener Colloquium

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ImmunityBio Reports Productive Meeting With Saudi FDA
    ImmunityBio Reports Productive Meeting With Saudi FDA

    17 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260217250658/en/ImmunityBio-Reports-Productive-Regulatory-Engagement-with-Saudi-Food-and-Drug-Authority-at-USA-Saudi-Biotech-Alliance-Meeting-Hosted-by-the-Ministry-of-Investment-of-Saudi-Arabia

    BUSINESSWIRE
    17 Feb 2026
    Share Share
    ImmunityBio Launches ANKTIVA Phase 2 Trial in Indolent Lymphomas
    ImmunityBio Launches ANKTIVA Phase 2 Trial in Indolent Lymphomas

    02 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-02/immunitybio-launches-phase-2-chemotherapy-free-car-nk-cell-therapy-trial-with-anktiva-resq215b-in

    PHARMIWEB
    02 Feb 2026
    Share Share
    ImmunityBio: OS Servival Not Reached in GBM with ANKTIVA CAR-NK
    ImmunityBio: OS Servival Not Reached in GBM with ANKTIVA CAR-NK

    23 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260123454593/en/ImmunityBio-Reports-Median-Overall-Survival-Not-Yet-Reached-and-Lymphopenia-Reversed-in-Recurrent-Glioblastoma-Patients-Receiving-ANKTIVA-Plus-CAR-NK-Chemo-Free-Therapy

    BUSINESSWIRE
    23 Jan 2026
    Share Share
    Immunitybio Progresses FDA Talks For ANKTIVA
    Immunitybio Progresses FDA Talks For ANKTIVA

    20 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-20/immunitybio-advances-regulatory-discussions-with-fda-on-potential-resubmission-path-for-anktiva-in

    PHARMIWEB
    20 Jan 2026
    Share Share
    Functional Force Platforms to Disrupt Tumors by 2026
    Functional Force Platforms to Disrupt Tumors by 2026

    16 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/functional-force-precision-platforms-disrupt-the-2026-tumor-landscape-302663334.html

    PR NEWSWIRE
    16 Jan 2026
    Share Share
    ImmunityBio Advances NMIBC Program on ANKTIVA Data
    ImmunityBio Advances NMIBC Program on ANKTIVA Data

    16 Jan 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-01-16/immunitybio-advances-first-line-bcg-naive-nmibc-program-with-enrollment-exceeding-expectations-and-p

    PHARMIWEB
    16 Jan 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search